Edition:
United States

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

16.15USD
28 Apr 2017
Change (% chg)

$0.60 (+3.86%)
Prev Close
$15.55
Open
$15.30
Day's High
$16.65
Day's Low
$15.30
Volume
547,052
Avg. Vol
264,714
52-wk High
$33.00
52-wk Low
$15.30

ACOR.OQ

Chart for ACOR.OQ

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.73
Market Cap(Mil.): $755.15
Shares Outstanding(Mil.): 46.76
Dividend: --
Yield (%): --

Financials

  ACOR.OQ Industry Sector
P/E (TTM): -- 58.40 30.08
EPS (TTM): -1.16 -- --
ROI: -4.85 -0.42 13.25
ROE: -7.79 5.87 14.41

BRIEF-Acorda qtrly GAAP net loss $0.41 per diluted share

* Acorda provides financial and pipeline update for first quarter 2017

Apr 27 2017

Acorda Therapeutics to cut 20 percent of workforce

Acorda Therapeutics Inc will cut nearly 20 percent of its workforce as part of a cost reduction plan, the company said on Wednesday, less than a week after losing certain patents for its multiple sclerosis (MS) drug, Ampyra.

Apr 05 2017

Acorda Therapeutics to cut 20 pct of workforce

April 5 Acorda Therapeutics Inc will cut nearly 20 percent of its workforce as part of a cost reduction plan, the company said on Wednesday, less than a week after losing certain patents for its multiple sclerosis (MS) drug, Ampyra.

Apr 05 2017

U.S. judge invalidates Acorda multiple sclerosis drug patents

A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted.

Mar 31 2017

U.S. judge invalidates Acorda multiple sclerosis drug patents

A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted.

Mar 31 2017

UPDATE 2-U.S. judge invalidates Acorda multiple sclerosis drug patents

March 31 A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted.

Mar 31 2017

BRIEF-U.S. district court invalidates four Acorda Therapeutics Ampyra patents

* U.S. district court issues decision to invalidate four Ampyra patents; company will appeal ruling

Mar 31 2017

U.S. judge invalidates Acorda multiple sclerosis drug patents

March 31 A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics related to its multiple sclerosis drug Ampyra.

Mar 31 2017

BRIEF-Acorda announces long-term safety data for CVT-301

* New drug application (NDA) submission planned by end Q2 2017

Mar 29 2017

Hedge fund manager Kyle Bass loses challenge to Acorda patents

By Jan Wolfe The U.S. Patent and Trademark Office on Thursday rejected hedge fund manager Kyle Bass' challenge to four patents on Acorda Therapeutics' flagship multiple sclerosis drug Ampyra.

Mar 10 2017

More From Around the Web

Earnings vs. Estimates